A large-scale database study for the prescription status of a new voltage-gated Ca²⁺ channel α₂δ ligand, mirogabalin, in Japan

References

• Japan Society of Pain Clinicians, eds. Guidelines for the pharmacological management of neuropathic pain. 2nd ed. Tokyo Japan: Shinko Trading Co., Ltd.; 2016. [cited 3 Aug 2021]. Japanese/English. Japanese/English: http://minds4.jcqhc.or.jp/minds/Pharmacologic-management-of-neuropathic-pain/Pharmacologic-management-of-neuropathic-pain.pdf
   Google Scholar
• Sommer C, Cruccu G. Topical treatment of peripheral neuropathic pain: applying the evidence. J Pain Symptom Manage. 2017;53:614–629.
   PubMed Web of Science ®Google Scholar
• de Leon-casasola O. New developments in the treatment algorithm for peripheral neuropathic pain. Pain Med. 2011;12(Suppl 3):S100–S108.
   PubMedGoogle Scholar
• Ushida T, Matsui D, Inoue T, et al. Recent prescription status of oral analgesics in Japan in real-world clinical settings: retrospective study using a large-scale prescription database. Expert Opin Pharmacother. 2019;20:2041–2052.
   PubMed Web of Science ®Google Scholar
• Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations. Lancet Neurol. 2015;14:162–173.
   PubMed Web of Science ®Google Scholar
• Yang M, Qian C, Liu Y. Suboptimal treatment of diabetic peripheral neuropathic pain in the United States. Pain Med. 2015;16:2075–2083.
   PubMed Web of Science ®Google Scholar
• Ushida T, Inoue T, Matsui D, et al. Cross-sectional study of patient satisfaction with oral analgesics in patients with chronic pain in Japan. Expert Opin Pharmacother. 2020;21:983–991.
   PubMed Web of Science ®Google Scholar
• Daiichi Sankyo Co., Ltd. Tarlige® (mirogabalin) Tablets 2.5 mg ∙ 5 mg ∙ 10 mg ∙ 15 mg, pharmaceutical product interview form. Japanese. [cited 28 Apr 2021]. Available from: https://www.info.pmda.go.jp/go/interview/1/430574_1190026F1028_1_TL6_1F.pdf
   Google Scholar
• Taiwan Food and Drug Administration. Assessment report. TARLIGE® F.C. Tablets 15 mg. [cited 22 Oct 2021]. Available from: https://www.fda.gov.tw/tc/includes/GetFile.ashx?id=f637368791343691781
   Google Scholar
• Domon Y, Arakawa N, Kubota K, et al. Analgesic effect of mirogabalin via the α2δ-1 subunit of voltage-gated calcium channels – evidence from α2δ-1 (R217A) and α2δ-2 (R282A) mutant mice –. Japanese. Jpn Pharmacol Ther. 2019;47:585–591.
   Google Scholar
• Kato J, Inoue T, and Yokoyama M, et al. A review of a new voltage-gated Ca2+ channel α2δ ligand, mirogabalin, for the treatment of peripheral neuropathic pain. Expert Opin Pharmacother. 2021;1–12. DOI:https://doi.org/10.1080/14656566.2021.1958780.
   Google Scholar
• Domon Y, Arakawa N, Inoue T, et al. Binding characteristics and analgesic effects of mirogabalin, a novel ligand for the α2δ subunit of voltage-gated calcium channels. J Pharmacol Exp Ther. 2018;365:573–582.
   PubMed Web of Science ®Google Scholar
• Baba M, Matsui N, Kuroha M, et al. Mirogabalin for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo-controlled phase III study in Asian patients. J Diabetes Investig. 2019;10:1299–1306.
   PubMed Web of Science ®Google Scholar
• Kato J, Matsui N, Kakehi Y, et al. Mirogabalin for the management of postherpetic neuralgia: a randomized, double-blind, placebo-controlled phase 3 study in Asian patients. Pain. 2019;160:1175–1185.
   PubMed Web of Science ®Google Scholar
• Kato J, Matsui N, Kakehi Y, et al. Long-term safety and efficacy of mirogabalin in Asian patients with postherpetic neuralgia: results from an open-label extension of a multicenter randomized, double-blind, placebo-controlled trial. Medicine (Baltimore). 2020;99:e21976.
   PubMed Web of Science ®Google Scholar
• Baba M, Matsui N, Kuroha M, et al. Long-term safety and efficacy of mirogabalin in Asian patients with diabetic peripheral neuropathic pain. J Diabetes Investig. 2020;11:693–698.
   PubMed Web of Science ®Google Scholar
• Daiichi Sankyo Co., Ltd. Tarlige® (mirogabalin) Tablets, 2.5 mg, 5 mg, 10 mg, 15 mg, package insert. [cited 28 Apr 2021]. Japanese. Japanese: https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/430574_1190026F1028_1_05
   Google Scholar
• Act on the protection of personal information (Amendment of Act No. 65 of 2015). [cited 28 Apr 2021]. Japanese. Japanese: https://www.ppc.go.jp/files/pdf/151112_kaiseian.pdf
   Google Scholar
• World Medical Association (WMA). WMA declaration of Helsinki - ethical principles for medical research involving human subjects. [cited 28 Apr 2021]. Available from: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/
   Google Scholar
• Guideline on implementation of pharmacoepidemiology studies in safety assessment of pharmaceuticals using database of medical information; 2014. [cited 3 Aug 2021]. Japanese. Japanese: https://www.pmda.go.jp/files/000147250.pdf
   Google Scholar
• Kimura Y, Yamaguchi S, Suzuki T, et al. Switching from pregabalin to mirogabalin in patients with peripheral neuropathic pain: a multi-center, prospective, single-arm, open-label study (MIROP Study). Pain Ther. 2021;10:711–727.
   PubMed Web of Science ®Google Scholar
• Hirakata M, Yoshida S, Tanaka-Mizuno S, et al. Pregabalin prescription for neuropathic pain and fibromyalgia: a descriptive study using administrative database in Japan. Pain Res Manag. 2018;2018:2786151.
   PubMed Web of Science ®Google Scholar
• Daiichi Sankyo Co., Ltd. An Asian, multicenter, randomized, double-blind, placebo-controlled, 14-week study of mirogabalin in participants with central neuropathic pain followed by a 52-week, open-label extension (NCT03901352). 2019. [cited 22 Oct 2021]. Available from: https://clinicaltrials.gov/ct2/show/NCT03901352
   Google Scholar
• Gilron I, Max MB. Combination pharmacotherapy for neuropathic pain: current evidence and future directions. Expert Rev Neurother. 2005;5:823–830.
   PubMedGoogle Scholar
• Baba M, Takatsuna H, Matsui N, et al. Mirogabalin in Japanese patients with renal impairment and pain associated with diabetic peripheral neuropathy or post-herpetic neuralgia: a phase III, open-Label, 14-week study. J Pain Res. 2020;13:1811–1821.
   PubMed Web of Science ®Google Scholar
• Arnold LM, Whitaker S, Hsu C, et al. Efficacy and safety of mirogabalin for the treatment of fibromyalgia: results from three 13-week randomized, double-blind, placebo- and active-controlled, parallel-group studies and a 52-week open-label extension study. Curr Med Res Opin. 2019;35:1825–1835.
   PubMed Web of Science ®Google Scholar